UC Davis study: Latino smokers in California on Medi-Cal still not getting help needed to quit

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A team of researchers with the UC Davis Comprehensive Cancer Center found that even with expanded access to Medi-Cal health coverage, Latino smokers in California continue to get less help than non-Latino white people quitting smoking.

Results from a cross-sectional study of 1,861 participants, published in JAMA Network Open, highlighted the inequity. 

The Affordable Care Act increased access to Medicaid, which is called Medi-Cal in California. 

By the fall of 2014, 2.8 million more people in the state gained access to Medi-Cal. Of these, 41% were newly insured non-elderly Latinos. The percentage of smokers covered by Medi-Cal increased substantially, from 19.3% before the ACA to 41.5% afterward.

The research shows that Latino smokers on Medi-Cal do not receive the same amount of tobacco cessation advice and assistance that non-Latino white smokers on Medi-Cal receive when they are seen by health professionals.

The lead author of the study, Cindy Valencia, said using strategies to engage tobacco users outside of a clinical encounter, such as proactive outreach and community-based engagement, may help address this disparity.

The study was conducted as part of Valencia’s PhD dissertation in Public Health Sciences. She is the first graduate of the program and a Latina.

Table of Contents

YOU MAY BE INTERESTED IN

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to the results of the phase III open-label, multicenter, randomized DeLLphi-305 study. 
Divarasib, a next-generation KRAS G12C inhibitor, lowered the risk of disease progression or death by 42% and the overall risk of death by 44% in people with previously treated KRAS G12C-mutated non-small cell lung cancer, according to the results from the phase III Krascendo 1 study. The therapy demonstrated the superior efficacy compared with current standard of care KRAS G12C inhibitors. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login